论文部分内容阅读
目的通过对160例肝癌患者血清AFP、CA199、CEA联合检测结果回顾性分析,探讨对肝癌诊断的价值。方法三种标志物均采用ELISA法同步检测。结果 AFP、CA199、CEA单项检测阳性率为67.5%、16.9%、14.4%,三项联合检测为81.9%;CA199和CEA在AFP阴性患者的阳性率为44.2%和36.5%;AFP在原发性与转移性肝癌组的阳性率(76.4%与5.0%)差异有统计学意义(P<0.001),CA199和CEA在转移性与原发性肝癌组的阳性率(80.0%、65.0%与7.9%、7.1%)差异亦均有统计学意义(P<0.001)。结论三项联检不仅能提高肝癌诊断的阳性率,且对鉴别原发性和转移性肝癌具有一定的临床诊断价值。
Objective To retrospectively analyze the combined results of serum AFP, CA199 and CEA in 160 patients with hepatocellular carcinoma (HCC) to explore the value of the combined detection of serum AFP, CA199 and CEA in the diagnosis of liver cancer. Methods All three markers were detected by ELISA. Results The positive rates of AFP, CA199 and CEA were 67.5%, 16.9% and 14.4%, respectively. The positive rates of CA199 and CEA in AFP negative patients were 44.2% and 36.5% (P <0.001). The positive rates of CA199 and CEA in metastatic and primary hepatocellular carcinoma (80.0%, 65.0% and 7.9%) were significantly higher than those in metastatic liver cancer (76.4% and 5.0% , 7.1%) were also statistically significant differences (P <0.001). Conclusion The three combined tests can not only improve the positive rate of diagnosis of liver cancer, but also have some clinical diagnostic value in the differential diagnosis of primary and metastatic liver cancer.